Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $100.09, for a total value of $1,501,350.00. Following the completion of the sale, the senior vice president now owns 28,239 shares of the company’s stock, valued at approximately $2,826,441.51. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Richard Paul Bryce also recently made the following trade(s):

  • On Thursday, July 20th, Richard Paul Bryce sold 1,998 shares of Puma Biotechnology stock. The stock was sold at an average price of $94.48, for a total value of $188,771.04.
  • On Monday, July 3rd, Richard Paul Bryce sold 5,000 shares of Puma Biotechnology stock. The stock was sold at an average price of $87.10, for a total value of $435,500.00.

Puma Biotechnology Inc (NYSE PBYI) traded down 2.93% on Friday, hitting $104.25. The stock had a trading volume of 850,226 shares. The firm’s market capitalization is $3.88 billion. The stock’s 50-day moving average is $88.12 and its 200 day moving average is $63.32. Puma Biotechnology Inc has a 1-year low of $28.35 and a 1-year high of $109.85.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by $0.78. On average, equities research analysts predict that Puma Biotechnology Inc will post ($8.60) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc (PBYI) SVP Richard Paul Bryce Sells 15,000 Shares” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/08/puma-biotechnology-inc-pbyi-svp-richard-paul-bryce-sells-15000-shares.html.

A number of large investors have recently made changes to their positions in the stock. Bank of Montreal Can grew its stake in Puma Biotechnology by 1.8% in the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 97 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Puma Biotechnology by 5.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 140 shares in the last quarter. Legal & General Group Plc grew its stake in Puma Biotechnology by 2.8% in the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 249 shares in the last quarter. Rhumbline Advisers grew its stake in Puma Biotechnology by 0.8% in the second quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock worth $2,948,000 after purchasing an additional 271 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Puma Biotechnology by 2.0% in the second quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock worth $1,950,000 after purchasing an additional 437 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors.

Several equities research analysts have weighed in on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $110.00 price objective (down previously from $118.00) on shares of Puma Biotechnology in a report on Thursday, August 10th. BidaskClub upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Friday. Citigroup Inc. upgraded Puma Biotechnology to a “buy” rating and set a $105.00 price objective for the company in a report on Sunday, May 28th. J P Morgan Chase & Co set a $105.00 price objective on Puma Biotechnology and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $125.00 price objective on shares of Puma Biotechnology in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $108.90.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.